CYP11B1 inhibitors(Steroid 11-beta-hydroxylase inhibitors), CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors), CYP21A2 inhibitors(Steroid 21 hydroxylase inhibitors)

Therapeutic Areas

Endocrinology and Metabolic DiseaseOther Diseases

Active Indication

Endogenous Cushing Syndrome

Inactive Indication

Diabetes Mellitus, Type 2

Originator Organization

Strongbridge Biopharma Plc

Active Organization

Cortendo ABStrongbridge Ireland Ltd.

Inactive Organization

DiObex, Inc.

License Organization

DiObex, Inc.

Strongbridge Biopharma Plc

Drug Highest PhaseApproved

First Approval Date

United States (30 Dec 2021),

Endogenous Cushing Syndrome

RegulationOrphan Drug (European Union)

Structure/Sequence

Molecular FormulaC26H28Cl2N4O4

InChIKeyXMAYWYJOQHXEEK-ZEQKJWHPSA-N

CAS Registry142128-57-2

Clinical Trials associated with Levoketoconazole

NCT04212000

/ CompletedPhase 1

A Phase 1 Randomized, Open-Label, Two-Period,Two-Sequence Crossover Study to Evaluate the Relative Oral Bioavailability of Levoketoconazole and Ketoconazole Tablets in Healthy Subjects

This is a phase 1, randomized, open-label, single-dose, two-period, two-sequence crossover study in healthy male and female subjects to evaluate the relative oral bioavailability of levoketoconazole tablets (the test drug) and ketoconazole tablets (the reference drug product).

Start Date16 Dec 2019

Sponsor / Collaborator

Cortendo AB

NCT03880825

/ CompletedPhase 1

A Phase I Open-Label, Fixed-Sequence Pharmacokinetic Drug Interaction Study to Evaluate the Effect of Levoketoconazole on the Single-Dose Pharmacokinetics of Metformin in Healthy Subjects

This is a phase I, open-label, fixed-sequence drug-drug interaction study to evaluate the effect of levoketoconazole on the single-dose PK of metformin in health subjects.

Start Date28 Mar 2019

Sponsor / Collaborator

Cortendo AB

NCT03621280

/ CompletedPhase 3

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

This is a long-term, open-label extension study of levoketoconazole in subjects with endogenous Cushing's Syndrome.

Start Date07 Jan 2019

Sponsor / Collaborator

Cortendo AB

100 Clinical Results associated with Levoketoconazole

100 Translational Medicine associated with Levoketoconazole

100 Patents (Medical) associated with Levoketoconazole

Literatures (Medical) associated with Levoketoconazole

01 Jul 2024·Indian Journal of Endocrinology and Metabolism

Efficacy and Safety of Levoketoconazole in Managing Cushing’s Syndrome: A Systematic Review

Review

Author: Dutta, Deep ; Raizada, Nishant ; Patra, Shinjan ; Nagendra, Lakshmi

AbstractNo systematic review has holistically analysed the efficacy and safety of levoketoconazole, a novel purified 2S,4R enantiomer of ketoconazole, believed to be 15- to 25-fold more potent than ketoconazole for managing Cushing’s syndrome (CS). We undertook this meta-analysis to address this knowledge gap. Electronic databases were searched for studies involving patients with CS receiving levoketoconazole in the intervention arm. The primary outcome was to evaluate changes in mean 24-hour urine-free cortisol (mUFC) levels. Secondary outcomes were to evaluate alterations in cortisol and adverse events. SONICS study showed that normalisation of mUFC was seen in 61%, 55%, and 41% of the patients at the end of 6, 9, and 12 months therapy, respectively. The LOGICs study showed that withdrawal of levoketoconazole was associated with a significant increase in mUFC from 81.3 ± 35.7 to 220.8 ± 333.5 nmol/24h. The late-night salivary-cortisol (LNSC) increase during the drug withdrawal phase was 2.6 nmol/L in the placebo group (PG) compared to 2.2 nmol/L in the levoketoconazole group (LG) (P < 0.05). Re-initiation of levoketoconazole in original LG was associated with a decrease in mUFC from 224.3 ± 341.3 to 135.6 ± 87.3 nmol/24h. Initiation of levoketoconazole in the original PG was associated with a decrease in mUFC from 537.9 ± 346.0 to 141.3 ± 130.3 nmol/24h. Normalisation of mUFC was observed in 50.0% patients in LG compared to 4.5% in the placebo group. The median time for the response was 25 days. The median time to loss of therapeutic response was significantly shorter for PG (24 days) compared to LG (62 days) (P < 0.0001). Levoketoconazole has good efficacy and safety in CS. Bigger and longer studies are warranted to establish its superiority over ketoconazole.

30 May 2023·Journal of Chromatographic Science

A New Strategy for the Software-Assisted LC Separations of Ketoconazole and Its Impurities

Article

Author: Bonde, Chandrakant ; Belemkar, Sateesh ; Agrawal, Roopali

AbstractAnalytical quality by design and the use of dissimilar chromatographic systems can be employed to accelerate chromatographic separations. Herein, a software (S-Matrix)-assisted platform was used to proficiently screen, optimize and select the optimal parameters for the chromatographic separation of ketoconazole and its related impurities. This approach evaluated the various chromatographic parameters in a stepwise manner based on the statistical tools and provided an in-depth understanding of the critical parameters influencing the peak selectivities and separations. It was demonstrated that dissimilar conditions, such as different stationary phases, mobile phase pH and organic modifiers (i.e., critical method variables), can improve the peak resolution, while the critical quality attributes can provide conditions appropriate for quantification purposes via a quality target analytical method. Furthermore, an orthogonal method was established to support the primary method. The orthogonality between the two methods was defined by the correlation matrix between the two systems using the Pearson correlation coefficient and was found to be 0.12. Using the optimized method, the primary method was validated as per International Council for Harmonization in the range of 0.05–1.0% for impurities and 80.0–120.0% for ketoconazole, thereby indicating the suitability of the method for use in quality control laboratories.

01 Dec 2022·Best Practice & Research Clinical Endocrinology & Metabolism

How best to monitor the specific side effects of medical treatments of Cushing’s disease

Review

Author: Castinetti, Frederic

The first-line treatment of Cushing's disease is transsphenoidal surgery. Medical treatment of Cushing's disease can be considered in several situations: as a presurgical treatment in patients with severe comorbidities, when surgery fails, or while waiting for the maximal efficacy of radiation techniques. Several modalities of medical treatment are possible, from adrenal-targeting drugs (steroidogenesis inhibitors) to pituitary-targeting drugs (somatostatin receptor ligand pasireotide or the dopamine agonist cabergoline), or even drugs that antagonize the glucocorticoid receptor (mifepristone). Given the morbidities associated with hypercortisolism, and the fact that medical treatment can be delivered on a long-term basis, it is important to obtain eucortisolism and to monitor the drug effectively. The efficacy of these drugs will not be detailed in this review, nor their roles in the therapeutic algorithm of Cushing's disease. This review will rather focus specifically on adverse events associated with these drugs (ketoconazole, levoketoconazole, metyrapone, osilodrostat, pasireotide, cabergoline and mifepristone), and the way in which to monitor and treat them, based on retrospective studies and the most recently published prospective studies.

News (Medical) associated with Levoketoconazole

21 Jan 2025

·www.prnewswire.com

The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness

Strategic collaboration formed to raise awareness that all people with diabetes on blood glucose-lowering medications should have glucagon, preferable a ready-to-use formulation CHICAGO and ARLINGTON, Va., Jan. 21, 2025 /PRNewswire/ -- The American Diabetes Association® (ADA) and Xeris Pharmaceuticals® (Xeris BioPharma Holdings, Inc.), a national supporter of the ADA, are pleased to announce a multi-year strategic partnership to reinforce the importance of prescribing glucagon, preferably ready-to-use, for all individuals with diabetes who are treated with insulin and/or insulin secretagogues or those at high risk of hypoglycemia (low blood glucose, also called low blood sugar), in line with the ADA's recently updated Standards of Care in Diabetes—2025 (Standards of Care).1 "Severe hypoglycemia is life-threatening, and people with diabetes on blood glucose-lowering medication are at risk for hypoglycemia. Thus, we must act with urgency to educate people about the importance of having a treatment plan in place that includes having glucagon on hand," said Charles "Chuck" Henderson, the ADA's chief executive officer. "Through this important partnership, we can save lives by ensuring individuals with diabetes who are treated with insulin have access to glucagon, preferably a ready-to-use formulation, so they can make a plan and be ready." It is estimated that up to 46% of people with type 1 diabetes and 21% of those with type 2 diabetes using insulin experience at least one severe hypoglycemia event each year.2 Hypoglycemia is conservatively responsible for more than 202,000 emergency department visits annually with approximately 25% being admitted to the hospital.3 This is unacceptable. More needs to be done to protect people at risk for severe hypoglycemia. The ADA, with support from Xeris, seeks to rectify the low rates of appropriate glucagon prescriptions by developing education materials and training resources for health care professionals and people living with diabetes, as well as through a national awareness campaign to educate people on who is at risk for severe hypoglycemia and should have glucagon, preferably ready-to-use, as a safety net. "Severe hypoglycemia is associated with up to a three-time increased risk of death in people with diabetes.4,5,6 Xeris is proud to collaborate with the ADA to urge adoption of their strengthened clinical practice recommendations around the treatment of severe hypoglycemia," said John Shannon, Xeris' CEO. "The stakes are too high for so many patients at risk to be without a safety net. Our mutual commitment is to fight for all patients living with diabetes and ensure that they can face severe low blood glucose emergencies with confidence by always having a ready-to-use glucagon on hand." To learn more about the importance of severe hypoglycemia, readiness and treatment options, visit diabetes.org/severehypo. About the American Diabetes Association The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. For 84 years, the ADA has driven discovery and research to prevent, manage, treat, and ultimately cure diabetes. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing's syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism as well as multiple early-stage programs leveraging Xeris' technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit , or follow us on X, LinkedIn, or Instagram. American Diabetes Association Professional Practice Committee; 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care 1 January 2025; 48 (Supplement_1): S128–S145. Stuckey HL, Desai U, King SB, et al. The experience of a severe hypoglycaemic event from the perspective of people with diabetes and their caregivers: "What am I going to do?". Diabet Med. 2022;39(4):e14745. doi:10.1111/dme.14745 Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed January 8, 2025. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36(5):1384-1395. doi:10.2337/dc12-2480 McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897-1901. doi:10.2337/dc11-2054 Zoungas S, Patel A, Chalmers J, et al. Severe Hypoglycemia and Risks of Vascular Events and Death. N Engl J Med. 2010;363(15):1410-1418. doi: 10.1056/NEJMoa1003795. Contact: Virginia Cramer, (703) 253-4927 [email protected] SOURCE American Diabetes Association WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3

10 Jan 2025

·xerispharma.com

Xeris Expects to Exceed Full-Year 2024 Financial Guidance

Full-year 2024 total revenue projected to be $203 million, exceeding previous guidance of $198-$202 million Year-end 2024 cash position expected to be over $71 million, generating positive cash flow in the fourth quarter Recorlev® net revenue Q4 2024 anticipated to increase by approximately $5 million or 28% sequentially 2024 financial results and 2025 outlook expected on March 6, 2025 CHICAGO--(BUSINESS WIRE)--Jan. 10, 2025-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced it expects to generate total 2024 revenue of $203 million, which will exceed previously announced 2024 total revenue guidance of $198 million to $202 million. The Company also anticipates ending 2024 with over $71 million in cash, cash equivalents, and short-term investments, generating positive cash flow in the fourth quarter. “We achieved another record quarter of exceptional total revenue growth with revenues expected to be $60 million for the fourth quarter and $203 million for the full year representing growth of 35% and 24%, respectively. These impressive results are driven by accelerating demand for Recorlev and continued strong Gvoke demand,” said John Shannon, CEO of Xeris. “Our focus remains on continuing to drive exceptional product revenue growth and advancing our robust pipeline - namely our Phase 3 ready, XP-8121 program. With our commercial engine leading the way and our strong balance sheet, we are well positioned for a transformational 2025.” Other Fourth Quarter 2024 Updates Recorlev® achieved record number of new starts and referrals. Gvoke® ended the year with approximately 35% market share. Keveyis® maintained a similar number of patients on therapy as Q3 2024. Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol® formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter. Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect® formulation technology. The termination will not have a material impact on Xeris’ outlook. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. Forward-Looking Statements Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the financial outlook for 2024, including quarterly product revenue, projections regarding year-end 2024 cash estimates and total revenue, company performance in 2025, the potential for growth of revenue, the market, demand and therapeutic potential of its products and product candidates, the potential utility of its formulation platforms, the advancement of its pipeline (including XP-8121), the impact of the termination of the Amgen license agreement on our outlook, the timing of the release of our financial results and outlook, and other statements containing the words “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The various factors that could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements, include, but are not limited to, its financial position and need for financing, including to fund its product development programs or commercialization efforts, whether its products will achieve and maintain market acceptance in a competitive business environment, its reliance on third-party suppliers, including single-source suppliers, its reliance on third parties to conduct clinical trials, the ability of its product candidates to compete successfully with existing and new drugs, and its and collaborators’ ability to protect its intellectual property and proprietary technology. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris can be found in Xeris’ filings, including those other risk factors identified in the “Risk Factors” and “Management's Discussion and Analysis of Financial Condition and Results of Operations” sections of Xeris' Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC), the contents of which are not incorporated by reference into, nor do they form part of, this communication. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.xerispharma.com, for a discussion of these and other risks and uncertainties. Forward-looking statements in this communication are based on information available to us, as of the date of this communication and, while we believe our assumptions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, we do not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on businesswire.com: https://www.businesswire.com/news/home/20250110463157/en/ Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma Holdings, Inc.

License out/inFinancial StatementPhase 3

26 Nov 2024

·xerispharma.com

Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Nov. 26, 2024-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 at 8:00am Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Xeris’ Investor Relations website at www.xerispharma.com. A replay of the webcast will be available for 30 days. About Xeris Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients' lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs to bring new products forward using its proprietary formulation technology platforms, XeriSol® and XeriJect®, supporting long-term product development and commercial success. Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on X, LinkedIn, or Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20241125772487/en/ Investor Contact Allison Wey Senior Vice President, Investor Relations and Corporate Communications awey@xerispharma.com Source: Xeris Biopharma

100 Deals associated with Levoketoconazole

External Link

KEGG	Wiki	ATC	Drug Bank
D10950	Levoketoconazole	-	DB05667

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Endogenous Cushing Syndrome	United States	Strongbridge Ireland Ltd.	30 Dec 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Endogenous Cushing Syndrome	Phase 3	France	Cortendo AB	01 Aug 2014
Endogenous Cushing Syndrome	Phase 3	Italy	Cortendo AB	01 Aug 2014
Endogenous Cushing Syndrome	Phase 3	Israel	Cortendo AB	01 Aug 2014
Endogenous Cushing Syndrome	Phase 3	Poland	Cortendo AB	01 Aug 2014
Endogenous Cushing Syndrome	Phase 3	Bulgaria	Cortendo AB	01 Aug 2014
Endogenous Cushing Syndrome	Phase 3	Spain	Cortendo AB	01 Aug 2014
Endogenous Cushing Syndrome	Phase 3	Netherlands	Cortendo AB	01 Aug 2014
Diabetes Mellitus, Type 2	Phase 2	United States	DiObex, Inc.	01 Jan 2008
Diabetes Mellitus, Type 2	Phase 2	Australia	DiObex, Inc.	01 Jan 2008
Diabetes Mellitus, Type 2	Phase 2	New Zealand	DiObex, Inc.	01 Jan 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01838551 (SONICS, Corporate Publications) Manual	Phase 3	Cushing Syndrome	92	Recorlev (Baseline mUFC≤2.5xULN)	(pfsuwidlsc) = zwiwuhgbhh cgbjhgowdi (mecjvmvpup, 0.16 - 0.47) View more	Positive	03 Jun 2024
				Recorlev (Baseline mUFC>2.5 to ≤5xULN)	(pfsuwidlsc) = znalwinrpb cgbjhgowdi (mecjvmvpup, 0.20 - 0.54) View more
SONICS Study (ENDO2024)	Phase 3	-	94	Levoketoconazole (Group 2: >2.5x to ≤5x ULN)	dpftxuzklx(cxhiyehzdi) = Group 3 had more liver-related adverse events of special interest than Group 1 or 2 (14% vs 7.9% or 3.0%) and more AEs leading to discontinuation (24% vs 12% or 16%) rsgpeymmwn (zfiyegsrvk )	Positive	01 Jun 2024
				Levoketoconazole (Group 3: >5x ULN)
ENDO2024	Not Applicable	-	3	Levoketoconazole 150 mg BID	xavckeacnu(ipwwbuqasx) = The other two patients are being carefully monitored for QTc abnormalities zwsfznuywh (ezkpdxyquo ) View more	-	01 Jun 2024
				Levoketoconazole 300 mg BID
Corporate Publications Manual	Phase 3	Cushing Syndrome	79	Levoketoconazole	dspahxrhxl(guwbxxgkmn) = zjfscweaxw ilwtbxqhqq (cfvudahlje ) View more	Positive	12 May 2022
				Placebo	dspahxrhxl(guwbxxgkmn) = nycnwnubqq ilwtbxqhqq (cfvudahlje ) View more
NCT03277690 (LOGICS, ENDO2021)	Phase 3	Endogenous Cushing Syndrome	84	Levoketoconazole	vhnvgenzrn(vphempkhev) = cddusgujfy cojxhqlkri (wadhmywpqx ) View more	Positive	03 May 2021
				Placebo	vhnvgenzrn(vphempkhev) = dzfrjebrsv cojxhqlkri (wadhmywpqx ) View more
NCT01838551 (SONICS, CTgov)	Phase 3	Endogenous Cushing Syndrome	94	Levoketoconazole	ozfpeeoiqj(orbspdclfk) = ruzzyhwboe uuyqbglais (ceissfczxw, ncgeoujwoy - ylamlsrnsk) View more	-	19 Apr 2021
NCT01838551 (SONICS, Pubmed \| Front Endocrinol (Lausanne))	Phase 3	Diabetes Mellitus \| Cushing Syndrome	94	Levoketoconazole (Patients with DM)	aqjjfisfln(bojwwzcqya): P-Value = 0.0006 View more	-	01 Jan 2021
				Levoketoconazole (Patients without DM)
NCT03277690 (LOGICS, Biospace) Manual	Phase 3	Endogenous Cushing Syndrome	44	RECORLEV	vwdunwrfqh(agybyfpubd) = tssbiayovz vlqciqilki (ufxswrgjgw ) View more	Positive	08 Sep 2020
				placebo	vwdunwrfqh(agybyfpubd) = dtbqawpuje vlqciqilki (ufxswrgjgw ) View more
NCT01838551 (SONICS, ENDO2019)	Phase 3	Diabetes Mellitus \| Cushing Syndrome Maintenance	94	Levoketoconazole	(sykbuthbhh) = bmdzgtzlnk chsnqtwynp (txiddabmnl ) View more	Positive	30 Apr 2019
				Placebo	(sykbuthbhh) = zclpujmecf chsnqtwynp (txiddabmnl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis